Community pharmacy reimbursement fair pricing requirement provision
Impact
The enactment of SF3299 is expected to enhance patient access to pharmacy services while simultaneously bolstering the financial viability of community pharmacies. By setting reimbursement standards, the bill aims to prevent below-cost reimbursements and negative adjustments that could undermine community pharmacies. Prohibiting such practices will provide these pharmacies with the financial support necessary to continue operating effectively, thereby reinforcing their role in the healthcare system, particularly in rural and underserved areas.
Summary
SF3299 is a legislative act aimed at ensuring fair pricing in reimbursement for community pharmacies in Minnesota. The bill mandates that the total reimbursement for any prescription drug dispensed by a community pharmacy must meet or exceed either the National Average Drug Acquisition Cost (NADAC) or, if NADAC is unavailable, the Wholesale Acquisition Cost (WAC). Additionally, it includes a requirement for a professional dispensing fee that is adjusted biennially based on a cost-of-dispensing survey to account for inflation and operational expenses.
Contention
During discussions surrounding the bill, notable contention emerged regarding the practices of pharmacy benefit managers (PBMs) and managed care organizations (MCOs). The bill seeks to establish parity in reimbursement, preventing PBM-owned pharmacies from being reimbursed at higher rates than community pharmacies for the same drug under similar conditions. This aspect of the bill is crucial as it addresses the existing disparities within pharmacy reimbursement frameworks, advocating for a level playing field that could impact how PBMs operate moving forward. Stakeholders indicate that while the bill may enhance community pharmacy operations, some are concerned about potential pushback from PBMs, which could challenge the bill's implementation and effectiveness.
Pharmacy benefit manager business practices modified, pharmacy benefit manager general reimbursement practices established, and maximum allowable cost pricing requirements modified.
Generic or off-patent drugs; excessive price increases prohibited, attorney general authorized to take action against price increases, sale withdrawal prohibited, prescription drug affordability board and advisory council established, prescription drug cost reviews and remedies provided, and money appropriated.
A bill for an act relating to pharmacy benefits managers, pharmacies, prescription drugs, and pharmacy services administrative organizations, and including applicability provisions. (Formerly SSB 1074.) Effective date: 07/01/2025. Applicability date: 07/01/2025.